Anavex Life Sciences Price-to-Tangible-Book Definition
As of today (2024-04-24), Anavex Life Sciences's share price is $3.425. Anavex Life Sciences's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $1.65. Hence, Anavex Life Sciences's Price to Tangible Book Ratio of today is 2.07.
The historical rank and industry rank for Anavex Life Sciences's Price-to-Tangible-Book or its related term are showing as below:
AVXL'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.81 Med: 7.63 Max: 46.25
Current: 2.08
During the past 13 years, Anavex Life Sciences's highest Price to Tangible Book Ratio was 46.25. The lowest was 1.81. And the median was 7.63.
AVXL's Price-to-Tangible-Book is ranked better than 56.98% of 1218
companies
in the Biotechnology industry
Industry Median: 2.69
vs AVXL: 2.08
A closely related ratio is called PB Ratio. As of today, Anavex Life Sciences's share price is $3.425. Anavex Life Sciences's Book Value per Sharefor the quarter that ended in Dec. 2023 was $1.65. Hence, Anavex Life Sciences's P/B Ratio of today is 2.07.
Anavex Life Sciences Price-to-Tangible-Book Historical Data
The historical data trend for Anavex Life Sciences's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Anavex Life Sciences's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anavex Life Sciences Price-to-Tangible-Book Distribution
For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Anavex Life Sciences's Price-to-Tangible-Book falls into.
Anavex Life Sciences Price-to-Tangible-Book Calculation
Anavex Life Sciences's price-to-tangible-book ratio for today is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Anavex Life Sciences Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Anavex Life Sciences's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Anavex Life Sciences (Anavex Life Sciences) Business Description
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AVXL has been successfully added to your 